Advocates warn over 10,000 Australians risk losing access to MS drugs
The Pharmaceutical Benefits Advisory Committee met on July 8, 2026, to address a dispute affecting multiple sclerosis patients. Advocates warn that over 10,000 Australians could face annual costs of $33,000 for essential drugs Ocrevus and Kesimpta if subsidized access is lost. Health Minister Mark Butler emphasized the necessity of keeping these medications.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 07 Jul 2026, 18:35 UTC · Updated 07 Jul 2026, 18:40 UTC
Summary by OZbrief Editorial. Original report: ABC News – Australia. Editorial policy · Corrections
Trending
- Breaking: Senior WA minister Paul Papalia set to resign, triggering by-election
- Lachie Perrem suffers severe burns after robotic vacuum explodes at home
- Pioneer of ‘extreme male brain’ theory of autism now says phrase unhelpful
- Farmers stuck with 'broken' standalone power systems
- Workplace watchdog rules on Jess Wilson’s forklift-driving social media stunt
- Make Ed Miliband chancellor, ex-chief Treasury adviser tells Andy Burnham